Clinical Trials Logo

Primary CNS Lymphoma clinical trials

View clinical trials related to Primary CNS Lymphoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03212807 Withdrawn - Clinical trials for Primary CNS Lymphoma

Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL

DuRIANS
Start date: August 2017
Phase: Phase 2
Study type: Interventional

PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL Patients with relapsed refractory subtypes of DLBCL who fulfill the inclusion / exclusion criteria will be recruited to this trial and treated in this open label, phase 2 trial with the PDL1 inhibitor Durvalumab and Lenalidomide. The combination treatment will be given from the time of recruitment for 6 months when Lenalidomide will be stopped but Durvalumab will continue for a total of 2 years. Response will be assessed by PET / CT scans as per standard lugano criteria.